Who’s Who with NTI: Neurotech Ieads the way in paediatric neurology treatments

In this latest episode of Stockhead’s Who’s Who on the ASX, host Tylah Tully spotlights Neurotech (ASX:NTI), a clinical-stage biopharmaceutical company developing innovative cannabinoid-based therapies for paediatric neurological disorders.

Neurotech’s lead drug candidate, NTI164, is a non-intoxicating, broad-spectrum oral cannabinoid formulation showing highly encouraging clinical results in Autism Spectrum Disorder, Rett Syndrome, and PANDAS/PANS.

With statistically significant improvements and excellent safety outcomes across multiple trials, the company is now advancing through key regulatory and commercialisation milestones.

Backed by orphan drug designations in the US and Europe, a strong intellectual property portfolio, and an experienced leadership team led by Chair Mark Davies and CEO Dr Anthony Filippis, Neurotech is positioned at a major inflection point. Its authorised prescriber program in Australia is already providing access for eligible paediatric patients, bridging innovation with real-world care.

With a potential multi-billion-dollar addressable market and positive clinical data, Neurotech International offers investors a unique entry into the rapidly growing field of next-generation cannabinoid therapeutics for childhood neurological conditions.

This video was developed in collaboration with Neurotech International, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.